Ardelyx, Inc. reported a 31% year-over-year revenue increase in Q2, driven by strong demand for its drugs IBSRELA and XPHOZAH. However, near-term revenue growth is limited by payer friction, leading to a lowered revenue guidance of $350 to $370 million. Management is addressing these access challenges by expanding reimbursement teams, optimizing pharmacy networks, and increasing sales efforts to convert demand into revenue. The company trades at a discount with profitability expected by 2027, and future valuation gains depend on resolving access issues and maintaining growth momentum.
Palantir has guided its revenue for the third quarter of 2026 to reach $2.16 billion. This forecast is supported by the company's performance in the last two quarters, which suggests that actual results could surpass expectations. The strong revenue ...
Quebec's maple syrup reserve, stored in warehouses with a capacity of about 218,000 barrels, is expected to be depleted by February. This reserve helps balance supply fluctuations caused by weather, which strongly affects syrup production. Canadian s...
Bitcoin has experienced significant price declines during U.S. midterm election cycles in 2010, 2014, 2018, and 2022, with drops ranging from 27% to 72%. However, the exact timing and cause of these declines are unclear due to lack of detailed data. ...
On October 24, XRP recorded the highest annualized funding rate of 10.9% among major cryptocurrencies in a futures market snapshot, indicating strong demand for long positions. Bitcoin followed with a 9.1% annualized rate and saw a 3.08% increase in ...
The Stellar Development Foundation released a software checklist for its Bell upgrade, detailing versions of Stellar Core, Horizon, SDKs, and other components ahead of November votes on Protocol 30. This upgrade introduces new features like W address...
